Crizotinib (Xalkori) 200mg & 250mg Capsules | China NMPA-Approved ALK/ROS1 Inhibitor for NSCLC | GLT

Generic Information: Xalkori (Crizotinib) — China Mainland Version

Xalkori, known inside China as 赛可瑞, is the originator crizotinib capsule developed by Pfizer. The China-Mainland pack is manufactured at Pfizer Manufacturing Deutschland GmbH in Freiburg, Germany, under marketing authorization holder PFIZER EUROPE MA EEIG, and is dispensed in bottles of 60 capsules in two strengths: 200 mg and 250 mg. Crizotinib opened the era of ALK-targeted lung cancer therapy and is still a cornerstone first-generation option for driver-gene-positive disease.

What Is Xalkori (Crizotinib) Used For?

In China, 赛可瑞 is prescribed for patients with locally advanced or metastatic non-small cell lung cancer whose tumors carry an ALK rearrangement or a ROS1 rearrangement, confirmed by an approved molecular test. Beyond lung cancer, crizotinib is also referenced globally for two rarer ALK-driven diseases: systemic anaplastic large cell lymphoma (ALCL) in children one year and older and young adults, and unresectable or recurrent inflammatory myofibroblastic tumor (IMT). Families facing these rarer diagnoses frequently contact GLT about access to the capsules from China.

How Does Xalkori Work?

The molecule blocks a family of receptor tyrosine kinases — ALK, ROS1, c-Met (HGFR) and RON. When the ALK or ROS1 gene is rearranged, tumor cells produce fusion proteins that keep growth signaling permanently switched on. Crizotinib wedges into the ATP-binding pocket of these kinases, dampening downstream PI3K/AKT and MAPK pathways, which slows cell division and nudges tumor cells into apoptosis. Across pooled analyses of the pivotal studies, objective response rates landed near 60% with disease control around 84%, and median progression-free survival ran in the eight-to-nine-month range for ALK-positive NSCLC; the ROS1 cohort showed objective responses in roughly two thirds of patients.

Approved Indications in China

• ALK-positive locally advanced or metastatic NSCLC, verified by an approved companion diagnostic
• ROS1-positive metastatic NSCLC per updated reference labeling
• International labels additionally cover ALK-positive systemic ALCL (age 1 year and older) and ALK-positive IMT

Dosage and Administration

Standard adult dosing for NSCLC is one 250 mg capsule taken twice daily, about twelve hours apart, with or without food. The 200 mg strength exists chiefly for dose-reduction steps. Capsules are swallowed whole; grapefruit and starfruit products are best avoided because they interfere with drug metabolism. In severe kidney impairment without dialysis, the schedule falls to 250 mg once daily; moderate liver impairment typically starts at 200 mg twice daily under oncologist supervision. Treatment usually continues until progression or unacceptable toxicity.

Side Effects of Xalkori

Everyday effects include brief visual trails or light flashes when moving between light and dark, nausea, diarrhea, vomiting, constipation, ankle swelling, tiredness and mild liver-enzyme rises. The label carries boxed-style warnings for hepatotoxicity, interstitial lung disease or pneumonitis, QT-interval prolongation, bradycardia and severe visual loss — which is why liver panels and ECGs are checked on a routine cycle, and vision changes must be reported quickly. Most toxicities are manageable with dose holds, reductions or supportive care.

Storage Instructions

Keep the bottles below 30°C in their original carton, away from moisture, with a shelf life of 36 months. No refrigeration is needed — ordinary room-temperature storage during shipping is sufficient.

Why Choose the China Version of Xalkori?

Mainland China runs one of the most mature access programs anywhere for this molecule. 赛可瑞 has been included in China's National Reimbursement Drug List, and successive national negotiations have pushed the reimbursed pharmacy price to roughly 70%–80% below the United States list price for capsules produced on the same German line. The launch-era Chinese price was several times higher; today both strengths flow through major hospital pharmacies at a sustainable cost. For patients abroad, GLT sources the authentic China pack directly, checks batch and expiry details, and arranges tracked international dispatch with full paperwork — German Pfizer quality at China-Mainland pricing.

How to Order Xalkori from GLT

Message GLT on WhatsApp at +86 15234153837 or write to [email protected] with your prescription and ALK/ROS1 test report. Our team confirms the strength (200 mg or 250 mg), quantity, current batch and total cost, then arranges cold-safe, discreet international shipping with full tracking and documentation. Inquiries from individual patients, caregivers, clinics and institutional buyers are all welcome.

FAQ: Buying Xalkori (Crizotinib) from China

Q1: Is Xalkori available in China?
Yes. The Pfizer originator capsules are marketed nationwide as 赛可瑞 and have been reimbursed through China's National Reimbursement Drug List for years.

Q2: How much does Xalkori cost in China?
The NRDL-negotiated pharmacy price sits roughly 70%–80% below the US list price for the same German-manufactured capsules; regional reimbursement then lowers out-of-pocket cost further.

Q3: Where can I buy Xalkori from China?
Through GLT: send your prescription and test report to WhatsApp +86 15234153837 or [email protected], and we handle sourcing, verification and international delivery.

Q4: What is the difference between the 200 mg and 250 mg capsules?
250 mg twice daily is the full starting dose; 200 mg is mainly a step-down strength used when doctors manage side effects.

Q5: Do you supply to hospitals and pharmacies as well as patients?
Yes. GLT serves individual families and institutional buyers alike, with batch documentation and export paperwork provided for every order.